Variations in Aggregation Structures and Fluorescence Properties of a Semialiphatic Fluorinated Polyimide Induced by Very High Pressure

Variations in the molecular aggregation structures and optical properties of a semialiphatic fluorinated 10FEDA/DCHM (poly­(4,4′-diaminocyclohexylmethane 1,4-bis­(3,4-dicarboxytrifluorophenoxy) tetrafluorobenzeneimide) polyimide (PI), which exhibits strong cyan fluorescence, were examined under very high pressure up to 8 GPa using synchrotron wide-angle X-ray diffraction (WAXD) and fluorescence spectroscopy. The fluorescence intensity of a PI film imidized at 220 °C was significantly reduced by applying pressure up to 1 GPa, which should be due to an appreciable reduction in interchain free volume, as indicated by a decrease in the <i>d</i>-spacing values of WAXD peaks which correspond to intermolecular ordering. In contrast, a PI film imidized at 300 °C, which exhibited weaker fluorescence than that imidized at 220 °C at atmospheric pressure, demonstrated a much smaller reduction in fluorescence intensity below 1 GPa. Such differences in pressure dependence clearly reflect the degrees of PI chain packing formed at different imidization temperatures. These phenomena induced by high pressure were almost reversible between pre- and postpressurization states with small hysteresis in the WAXD patterns and fluorescence spectra

Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory disease that can affect multiple generations and cause complications with long-term prednisolone treatment. This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF) in preventing NMOSD relapse while reducing prednisolone dosage. The trial involved nine patients with NMOSD who received MMF along with prednisolone dose reduction. MMF was effective in achieving prednisolone dose reduction without relapse in 77.8% of patients, with a significant decrease in mean annualized relapse rate. All adverse events were mild. The findings suggest that MMF could be a viable treatment option for middle-aged and older patients who require steroid reduction. Clinical trial registration number: jRCT, jRCTs051180080. Registered February 27th, 2019-retrospectively registered, https://jrct.niph.go.jp/en-latest-detail/jRCTs051180080.</p